
CLAIMS

1. A compound of Formula Ic:



or the pharmaceutically acceptable salt thereof;

wherein:

Y is NR^1R^2;

R^1 is methyl;

R^2 is hydrogen;

R^3 is hydrogen;

R^7 is hydrogen, $C_{1\text{-}6}$alkyl, $C_{3\text{-}7}$cycloalkyl, heteroaryl, heterocyclic, or aryl;

R^8 is hydrogen or $C_{1\text{-}6}$alkyl;

R^{9a} and R^{9b} are selected from:

(i) independently selected from hydrogen, $C_{1\text{-}6}$alkyl, cycloalkyl, $-(CH_2)_c(NR^{9'})_2$, $C_{1\text{-}6}$hydroxyalkyl, $-CH_2SH$, $-(CH_2)_3NHC(=NH)NH_2$, $-(CH_2)_cCOR^{9''}$, aryl and aryl($C_{1\text{-}3}$alkyl)-; or

(ii) both $(CH_2)_r$ so as to form a spiro ring; or

(iii) R^{9a} is hydrogen and R^{9b} and R^8 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms; or

(iv) R^{9b} is hydrogen and R^{9a} and R^8 together are $(CH_2)_n$ so as to form a cyclic ring that includes the adjoining N and C atoms; or

(v) R^{9a} is hydrogen and R^{9b} is $-CH_2CH_2SCH_3$, $-CH_2CO_2H$, $-CH_2C(O)NH_2$, $-CH_2CH_2COOH$, $-CH_2CH_2C(O)NH_2$, $-CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$, or; or

(vi) R^{9a} is $-CH_2CH_2SCH_3$, $-CH_2CO_2H$, $-CH_2C(O)NH_2$, $-CH_2CH_2COOH$, $-CH_2CH_2C(O)NH_2$, $-CH_2CH_2CH_2CH_2NH_2$, $-CH_2CH_2CH_2NHC(NH)NH_2$ and R^{9b} is hydrogen;

$R^{9'}$ is independently selected from hydrogen and C_{1-6}alkyl;

$R^{9''}$ is $-OR^{11}$;

R^{10} is hydrogen, C_{1-6}alkyl, C_{1-6}haloalkyl, C_{3-7}cycloalkyl, heterocycloalkyl, aminoacyl, aryl, or heteroaryl;

R^{11} is C_{1-6}alkyl, cycloalkyl, C_{2-6}alkynyl, C_{2-6}alkenyl, or acyl;

c is 1 to 6;

r is 2 to 5; and

n is 2 to 4.

2. The compound of claim 1,
wherein:
R^7 is aryl;
R^8 is hydrogen or C_1-C_4alkyl;
R^{9a} is C_1-C_6alkyl;
R^{9b} is hydrogen; and
R^{10} is C_1-C_6alkyl.

3. The compound of claim 2, wherein R^7 is phenyl.

4. The compound of claim 2, wherein R^7 is napthyl.

5. The compound of any one of claims 1-4, wherein R^8 is hydrogen.

6. The compound of any one of claim 1-4, wherein R^8 is methyl.

7. The compound of claim 1, wherein R^{9a} and R^{9b} are both C_{1-6}alkyl.

8. The compound of claim 7, wherein R^{9a} and R^{9b} are methyl.

9. The compound of claim 1, wherein R^{9a} is methyl and R^{9b} is hydrogen.

10. The compound of any one of claim 1-9, wherein R^{10} is methyl, ethyl, or iso-propyl.

11. The compound of claim 10, wherein R^{10} is isopropyl.

12. The compound of any one of claims 1-11, wherein a deuterium is substituted for hydrogen at one or more locations on the molecule.

13. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1-12 in a pharmaceutically acceptable carrier to treat HCV in a host.

14. The pharmaceutical composition of claim 13, in an oral dosage form.

15. The pharmaceutical composition of claim 14, in a tablet.

16. The pharmaceutical composition of claim 14, in a capsule.

17. A compound of any one of claims 1-12, optionally in a pharmaceutically acceptable carrier, for use in the treatment of HCV in a host.

18. The compound of claim 17, wherein the compound is to be administered in combination with another anti-HCV agent.

19. The compound of claim 18, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.

20. The compound of any one of claims 17-19, wherein the host is a human.


21. Use of a compound of any one of claims 1-12, optionally in a pharmaceutically acceptable carrier, in the preparation of a medicament for the treatment of HCV in a host.

22. The use of claim 21, wherein the medicament is to be administered in combination with another anti-HCV agent.

23. The use of claim 22, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.


24. The use of claim any one of claims 21-23, wherein the host is a human.

25. A compound of the formula:




or a pharmaceutically acceptable salt thereof.

26. The compound of claim 25 of the formula:




or a pharmaceutically acceptable salt thereof.

27. The compound of claim 25 of the formula:




or a pharmaceutically acceptable salt thereof.

28. A compound of the formula:




or a pharmaceutically acceptable salt thereof.

29. The compound of claim 28 of the formula:



or a pharmaceutically acceptable salt thereof.

30. The compound of claim 28 of the formula:



or a pharmaceutically acceptable salt thereof.

31. The compound of any one of claims 25-30, wherein a deuterium is substituted for hydrogen at one or more locations on the molecule.

32. A pharmaceutical composition comprising an effective amount of a compound of any one of claims 25-31 in a pharmaceutically acceptable carrier to treat HCV in a host.

33. The pharmaceutical composition of claim 32, in an oral dosage form.

34. The pharmaceutical composition of claim 33, in a tablet.

35. The pharmaceutical composition of claim 33, in a capsule.

36. A compound of any one of claims 25-31, optionally in a pharmaceutically acceptable carrier, for use in the treatment of HCV in a host.

37. The compound of claim 36, wherein the compound is to be administered in combination with another anti-HCV agent.

38. The compound of claim 37, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.

39. The compound of any one of claims 36-38, wherein the host is a human.

40. Use of any one of claims 25-31, optionally in a pharmaceutically acceptable carrier, in the preparation of a medicament for the treatment of HCV in a host.

41. The use of claim 40, wherein the medicament is to be administered in combination with another anti-HCV agent.

42. The use of claim 41, wherein the additional anti-HCV agent is selected from the group consisting of an NS5A inhibitor, an NS5B polymerase inhibitor, or an NS3/4A protease inhibitor.

43. The use of any one of claims 40-42, wherein the host is a human.